Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Funding for Orphan Disease Indication Will Compare EpiVax's Tregitope with IVIG

PROVIDENCE, R.I., Nov. 16, 2012 /PRNewswire/ -- Full Article Here

(Logo:  http://photos.prnewswire.com/prnh/20121116/NE15175LOGO )

Providence-based biotech company EpiVax, Inc. was awarded a new $55,000 grant from the GBS-CIDP Foundation International, to explore using Tregitopes as a novel immuno-modulator therapy for a nerve disease that is currently treated with intravenous immunoglobulin G (IVIG). This award and the recent addition of an SBIR grant for $600,000 to explore the use of Tregitope for Pompe disease (August 2012) will bring the total amount of funding awarded to EpiVax for research and development of Tregitopes to $3.4M in 2012. The surge in funding will result in expansion at the Providence-based biotech company, that is working on spinning off the Tregitope technology into a new venture or angel-backed company.

The GBS-CIDP Foundation research funds will be devoted to developing a safer, more effective replacement for IVIG in the treatment of patients with CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). CIDP patients develop a debilitating nerve condition that requires treatment with IVIG. A single dose of IVIG costs $8,000, and patients often spend tens of thousands of dollars obtaining treatment per year. Alternative treatments that might redirect the immune response toward antigen-specific tolerance without immunosuppressive agents are needed.

The company has been extremely successful in SBIR funding for the Tregitope endeavor despite the constrained funding environment. SBIR grants awarded to EpiVax this year include a Phase I for testing the ability for Tregitopes to reduce inhibitors to FVIII, a separate Phase I SBIR for testing the ability of Tregitopes to reduce immune responses to GAA, a protein that is deficient in Pompe's disease, and a Phase II award to perform safety, toxicity and formulation studies on Tregitopes in the NOD model of Type 1 Diabetes.

About Tregitopes

Tregitopes are linear sequences of peptides contained within the framework of monoclonal antibodies and immunoglobulin-G ,which activate natural regulatory T cells. Tregitopes act as a natural 'off switch' and have been shown in standard preclinical models, and by collaborating laboratories, to suppress and treat autoimmune disease, allergies, and to effectively suppress the immunogenicity of co-administered proteins. This is a natural mechanism for suppressing tissue-destroying immune cells that are the root cause of 'organ-specific autoimmune diseases', in addition, modifying immune responses to biotherapeutics (such as FVIII and other biologics).

Tregitopes were discovered by the team of Anne S. De Groot and Bill Martin at EpiVax.

www.EpiVax.com

CONTACT:  Anthony Marcello, +1-401-272-2123, amarcello@epivax.com

SOURCE EpiVax, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
Enthusiasm for the Internet of Things has reached an all-time high. In 2013 alone, venture capitalists spent more than $1 billion dollars investing in the IoT space. With “smart” appliances and devices, IoT covers wearable smart devices, cloud services to hardware companies. Nest...
Bring the world's best IaaS to the world's best PaaS. In his session at 15th Cloud Expo, Animesh Singh, a Senior Cloud Architect and Strategist for IBM Cloud Labs, will share his experiences of running Cloud Foundry on OpenStack. He will focus on how Cloud Foundry and OpenStack c...
The move to the cloud brings a number of new security challenges, but the application remains your last line of defense. In his session at 15th Cloud Expo, Arthur Hicken, Evangelist at Parasoft, to discuss how developers are extremely well-poised to perform tasks critical for s...
It’s time to face reality: "Americans are from Mars, Europeans are from Venus," and in today’s increasingly connected world, understanding “inter-planetary” alignments and deviations is mission-critical for cloud. In her session at 15th Cloud Expo, Evelyn de Souza, Data Privacy a...
As enterprises look to take advantage of the cloud, they need to understand the importance of safeguarding their confidential and sensitive data in cloud environments. Enterprises must protect their data from (i) system administrators who don’t need to see the data in the clear a...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

DALLAS, September 20, 2014 /PRNewswire/ --